Its pan-cancer immunomodulatory effects may be mediated through STAT1-IDO1 signaling (60) or NF-κB-driven inflammatory pathways (65), ultimately promoting Treg infiltration and immune checkpoint expression (64). The gene discussed is NFKB1; the disease is cancer.